SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-039892
Filing Date
2023-11-08
Accepted
2023-11-08 16:01:53
Documents
73
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 720378
2 form10-q_001.jpg GRAPHIC 10738
3 ex31-1.htm EX-31.1 11539
4 ex31-2.htm EX-31.2 11510
5 ex32-1.htm EX-32.1 4895
  Complete submission text file 0001493152-23-039892.txt   4307264

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE mtnb-20230930.xsd EX-101.SCH 38400
7 XBRL CALCULATION FILE mtnb-20230930_cal.xml EX-101.CAL 52745
8 XBRL DEFINITION FILE mtnb-20230930_def.xml EX-101.DEF 98921
9 XBRL LABEL FILE mtnb-20230930_lab.xml EX-101.LAB 320462
10 XBRL PRESENTATION FILE mtnb-20230930_pre.xml EX-101.PRE 255111
67 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 560536
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

IRS No.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38022 | Film No.: 231387684
SIC: 2834 Pharmaceutical Preparations